PURPOSE: To determine the incremental benefit of combined endorectal magnetic resonance (MR) imaging and MR spectroscopic imaging, as compared with endorectal MR imaging alone, for sextant localization of peripheral zone (PZ) prostate cancer. MATERIALS AND METHODS: This prospective multicenter study, conducted by the American College of Radiology Imaging Network (ACRIN) from February 2004 to June 2005, was institutional review board approved and HIPAA compliant. Research associates were required to follow consent guidelines approved by the Office for Human Research Protection and established by the institutional review boards. One hundred thirty-four patients with biopsy-proved prostate adenocarcinoma and scheduled to undergo radical prostatectomy were recruited at seven institutions. T1-weighted, T2-weighted, and spectroscopic MR sequences were performed at 1.5 T by using a pelvic phased-array coil in combination with an endorectal coil. Eight readers independently rated the likelihood of the presence of PZ cancer in each sextant by using a five-point scale-first on MR images alone and later on combined MR-MR spectroscopic images. Areas under the receiver operating characteristic curve (AUCs) were calculated with sextant as the unit of analysis. The presence or absence of cancer at centralized histopathologic evaluation of prostate specimens was the reference standard. Reader-specific receiver operating characteristic curves for values obtained with MR imaging alone and with combined MR imaging-MR spectroscopic imaging were developed. The AUCs were estimated by using Mann-Whitney statistics and appropriate 95% confidence intervals. RESULTS: Complete data were available for 110 patients (mean age, 58 years; range, 45-72 years). MR imaging alone and combined MR imaging-MR spectroscopic imaging had similar accuracy in PZ cancer localization (AUC, 0.60 vs 0.58, respectively; P > .05). AUCs for individual readers were 0.57-0.63 for MR imaging alone and 0.54-0.61 for combined MR imaging-MR spectroscopic imaging. CONCLUSION: In patients who undergo radical prostatectomy, the accuracy of combined 1.5-T endorectal MR imaging-MR spectroscopic imaging for sextant localization of PZ prostate cancer is equal to that of MR imaging alone.
PURPOSE: To determine the incremental benefit of combined endorectal magnetic resonance (MR) imaging and MR spectroscopic imaging, as compared with endorectal MR imaging alone, for sextant localization of peripheral zone (PZ) prostate cancer. MATERIALS AND METHODS: This prospective multicenter study, conducted by the American College of Radiology Imaging Network (ACRIN) from February 2004 to June 2005, was institutional review board approved and HIPAA compliant. Research associates were required to follow consent guidelines approved by the Office for Human Research Protection and established by the institutional review boards. One hundred thirty-four patients with biopsy-proved prostate adenocarcinoma and scheduled to undergo radical prostatectomy were recruited at seven institutions. T1-weighted, T2-weighted, and spectroscopic MR sequences were performed at 1.5 T by using a pelvic phased-array coil in combination with an endorectal coil. Eight readers independently rated the likelihood of the presence of PZ cancer in each sextant by using a five-point scale-first on MR images alone and later on combined MR-MR spectroscopic images. Areas under the receiver operating characteristic curve (AUCs) were calculated with sextant as the unit of analysis. The presence or absence of cancer at centralized histopathologic evaluation of prostate specimens was the reference standard. Reader-specific receiver operating characteristic curves for values obtained with MR imaging alone and with combined MR imaging-MR spectroscopic imaging were developed. The AUCs were estimated by using Mann-Whitney statistics and appropriate 95% confidence intervals. RESULTS: Complete data were available for 110 patients (mean age, 58 years; range, 45-72 years). MR imaging alone and combined MR imaging-MR spectroscopic imaging had similar accuracy in PZ cancer localization (AUC, 0.60 vs 0.58, respectively; P > .05). AUCs for individual readers were 0.57-0.63 for MR imaging alone and 0.54-0.61 for combined MR imaging-MR spectroscopic imaging. CONCLUSION: In patients who undergo radical prostatectomy, the accuracy of combined 1.5-T endorectal MR imaging-MR spectroscopic imaging for sextant localization of PZ prostate cancer is equal to that of MR imaging alone.
Authors: Jurgen J Fütterer; Tom W J Scheenen; Henkjan J Huisman; Dennis W J Klomp; Ferdi A van Dorsten; Christina A Hulsbergen-van de Kaa; J Alfred Witjes; Arend Heerschap; Jelle O Barentsz Journal: Invest Radiol Date: 2004-11 Impact factor: 6.016
Authors: M D Rifkin; E A Zerhouni; C A Gatsonis; L E Quint; D M Paushter; J I Epstein; U Hamper; P C Walsh; B J McNeil Journal: N Engl J Med Date: 1990-09-06 Impact factor: 91.245
Authors: A V D'Amico; R Whittington; B Malkowicz; M Schnall; D Schultz; K Cote; J E Tomaszewski; A Wein Journal: J Urol Date: 2000-09 Impact factor: 7.450
Authors: Fergus V Coakley; John Kurhanewicz; Ying Lu; Kirk D Jones; Mark G Swanson; Silvia D Chang; Peter R Carroll; Hedvig Hricak Journal: Radiology Date: 2002-04 Impact factor: 11.105
Authors: Kristen L Zakian; Steven Eberhardt; Hedvig Hricak; Amita Shukla-Dave; Shanon Kleinman; Manickam Muruganandham; Kanishka Sircar; Michael W Kattan; Victor E Reuter; Peter T Scardino; Jason A Koutcher Journal: Radiology Date: 2003-08-14 Impact factor: 11.105
Authors: Stephan H Polanec; Katja Pinker-Domenig; Peter Brader; Dietmar Georg; Shahrokh Shariat; Claudio Spick; Martin Susani; Thomas H Helbich; Pascal A Baltzer Journal: World J Urol Date: 2015-09-25 Impact factor: 4.226
Authors: M C Roethke; T H Kuru; S Schultze; D Tichy; A Kopp-Schneider; M Fenchel; H-P Schlemmer; B A Hadaschik Journal: Eur Radiol Date: 2013-10-03 Impact factor: 5.315
Authors: Graham Sommer; Donna Bouley; Harcharan Gill; Bruce Daniel; Kim Butts Pauly; Chris Diederich Journal: Can J Urol Date: 2013-04 Impact factor: 1.344
Authors: A V Taira; G S Merrick; R W Galbreath; H Andreini; W Taubenslag; R Curtis; W M Butler; E Adamovich; K E Wallner Journal: Prostate Cancer Prostatic Dis Date: 2009-09-29 Impact factor: 5.554